PHS
APLS

PFM Health Sciences’s Apellis Pharmaceuticals APLS Stock Holding History

PFM Health Sciences’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-82,952
Closed -$3.18M – 76
2024
Q2 		$3.18M Hold
82,952
– – 0.16% 61
2024
Q1 		$4.88M Buy
+82,952
New +$5.29M 0.23% 68
2023
Q3 		– Sell
-274,498
Closed -$25M – 73
2023
Q2 		$25M Sell
274,498
-9,771
-3% -$843K 0.97% 42
2023
Q1 		$18.8M Sell
284,269
-34,153
-11% -$1.97M 0.83% 45
2022
Q4 		$16.5M Buy
318,422
+196,542
+161% +$10.4M 0.59% 56
2022
Q3 		$8.32M Buy
+121,880
New +$7.21M 0.3% 68

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

PFM Health Sciences's APLS Position: Q3 2024 in Review

PFM Health Sciences sold out of Apellis Pharmaceuticals (APLS) in Q3 2024, closing a stake of 82,952 shares — an estimated $3.18M sold.

PFM Health Sciences first reported a position in APLS in Q3 2022 and held it in 6 quarters. The position peaked at $25M in Q2 2023. 265 funds tracked by Wall St. Rank hold APLS as of Q3 2024.

  • PFM Health Sciences reported no remaining Apellis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • PFM Health Sciences sold 82,952 Apellis Pharmaceuticals shares in Q3 2024, an estimated $3.18M.
  • PFM Health Sciences first reported a position in Apellis Pharmaceuticals in Q3 2022 and held it in 6 quarters.
  • PFM Health Sciences's Apellis Pharmaceuticals position peaked at $25M in Q2 2023.
  • 265 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2024.

Based on PFM Health Sciences's 13F filing for Q3 2024, filed 14 Nov 2024.